CONMED (NYSE:CNMD) Issues FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 4.540-4.610 for the period, compared to the consensus estimate of 4.540. The company issued revenue guidance of $1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Ratings Changes

CNMD has been the subject of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Weiss Ratings upgraded shares of CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 21st. BMO Capital Markets began coverage on shares of CONMED in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 target price for the company. Zacks Research upgraded shares of CONMED from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Piper Sandler reissued a “neutral” rating and set a $45.00 price target (up from $39.00) on shares of CONMED in a research report on Thursday, July 30th. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $44.00.

CONMED Stock Down 3.3%

CNMD stock opened at $44.21 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.49 and a debt-to-equity ratio of 0.60. The business has a 50 day moving average price of $47.06 and a two-hundred day moving average price of $41.45. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 18.27, a P/E/G ratio of 2.00 and a beta of 0.94. CONMED has a twelve month low of $31.44 and a twelve month high of $53.66.

CONMED (NYSE:CNMD) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. The company had revenue of $335.56 million for the quarter, compared to analysts’ expectations of $336.28 million. CONMED had a return on equity of 13.93% and a net margin of 5.36%. The business’s revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.08 EPS. Analysts anticipate that CONMED will post 4.58 EPS for the current fiscal year.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED raised its fiscal 2026 EPS outlook to $4.54-$4.61, with the midpoint above the $4.54 analyst consensus. The company maintained revenue guidance of approximately $1.4 billion, in line with expectations. CONMED Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Third-quarter adjusted earnings of $1.04 per share exceeded the $1.00 consensus estimate. JPMorgan raised its price target from $45 to $50, while Wells Fargo increased its target from $46 to $49, suggesting analysts see additional upside. CONMED Q3 Earnings Top Estimates
• Neutral Sentiment: Both JPMorgan and Wells Fargo retained neutral-style ratings—“neutral” and “equal weight”—despite their higher targets. This indicates improved valuation expectations but no strong bullish conviction.
• Negative Sentiment: Quarterly revenue of approximately $335.6 million was essentially in line with estimates but declined about 0.7% year over year. EPS also fell from $1.08 in the prior-year quarter, signaling limited near-term operating momentum. CONMED Q3 Profit Rises and Updates 2026 Guidance

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.